Search Results

ThermoGenesis Holdings, Inc. reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update.

ThermoGenesis Holdings, Inc. today announced that Chris Xu , Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2023, and provide a corporate strategic update on Thursday, November 13, 2023, after the close of trading.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update.

ThermoGenesis Holdings, Inc. announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, announced the appointments of Biao Xi, Ph.D. and James Xu, Esq., DBA, PsyD., J.D., CPA to its Board, effective July 17, 2023.

ThermoGenesis Holdings, Inc. reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the first quarter ended March 31, 2023 and provided a corporate strategic update.

ThermoGenesis Holdings, Inc. announced that the Company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy companies.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading.